AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7528939 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nasal decongestant and position
Number of subjects: 20
Study 3169044 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (quinidine, disopyramide or mexiletine)
Number of subjects: 96
Study 3169044 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 96
Study 31748596 — intervention group
Group type: EXPERIMENTAL
Intervention: Noisy galvanic vestibular stimulation (nGVS)
Number of subjects: 30
Study 28272198 — intervention group
Group type: EXPERIMENTAL
Intervention: Practicing VR games during computer classes (including 15 minutes for practicing games in VR environment)
Number of subjects: 0
Study 28272198 — intervention group
Group type: COMPARATOR
Intervention: Computer classes (typical classes without VR games)
Number of subjects: 0
Study 25338927 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 38
Study 25338927 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 38
Study 23512974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (reduction of daily caloric intake by 400 kcal for 6 months)
Number of subjects: 33
Study 23512974 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal activity during a food specific memory task
Number of subjects: 33
Study 21192145 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (40 patients) for 12 weeks
Number of subjects: 80
Study 21192145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (40 patients) for 12 weeks
Number of subjects: 80
Study 19553555 — intervention group
Group type: EXPERIMENTAL
Intervention: N. lactamica OMV vaccine
Number of subjects: 97
Study 19553555 — intervention group
Group type: COMPARATOR
Intervention: Alhydrogel control
Number of subjects: 97
Study 17785386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental amalgam
Number of subjects: 534
Study 17785386 — intervention group
Group type: COMPARATOR
Intervention: Mercury-free resin-based composite
Number of subjects: 534
Study 15119883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss Collagen with a resorbable collagen barrier (Bio‐Gide)
Number of subjects: 4
Study 15119883 — intervention group
Group type: COMPARATOR
Intervention: Bio‐Oss Collagen without a resorbable collagen barrier
Number of subjects: 4
Study 11350721 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 314
Study 11350721 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention
Number of subjects: 314
Study 11350721 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer intervention
Number of subjects: 314
Study 9797642 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose polyester (SPE) 20-40 g daily (mean 26.8 g)
Number of subjects: 0
Study 9797642 — intervention group
Group type: COMPARATOR
Intervention: Control fat
Number of subjects: 0
Study 7657768 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis patients
Number of subjects: 55
Study 7657768 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 2545640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre supplement of 7 g/day for 11 weeks (part I)
Number of subjects: 97
Study 2545640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre supplement of 6 g/day for 16 weeks (part II)
Number of subjects: 97
Study 2545640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre supplement of 6 g/day and an ad libitum diet for the rest of the period (part III)
Number of subjects: 97
Study 2545640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre group
Number of subjects: 97
Study 2545640 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 97
Study 1102879 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release 40 mg dicyclomine hydrochloride tablets (Merbentyl Dospan)
Number of subjects: 0
Study 1102879 — intervention group
Group type: COMPARATOR
Intervention: 20 mg plain dicyclomine hydrochloride tablets (Merbentyl)
Number of subjects: 0
Study 31775518 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐acetylcysteine with a combination of nutraceuticals
Number of subjects: 145
Study 31775518 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐acetylcysteine alone
Number of subjects: 145
Study 31775518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 30973001 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 60
Study 30973001 — intervention group
Group type: COMPARATOR
Intervention: Intermittent renal replacement therapy (IRRT)
Number of subjects: 60
Study 29025845 — intervention group
Group type: EXPERIMENTAL
Intervention: MPMRI-targeted biopsy
Number of subjects: 470
Study 29025845 — intervention group
Group type: COMPARATOR
Intervention: TRUS biopsy
Number of subjects: 470
Study 25758601 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography (ICGA)
Number of subjects: 61
Study 25758601 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour fundus photography
Number of subjects: 61
Study 25758601 — intervention group
Group type: EXPERIMENTAL
Intervention: ICGA
Number of subjects: 61
Study 22939927 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLF)
Number of subjects: 555
Study 22939927 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 555
Study 21808295 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 0
Study 21808295 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19863177 — intervention group
Group type: EXPERIMENTAL
Intervention: (R-)CHOP
Number of subjects: 175
Study 19863177 — intervention group
Group type: COMPARATOR
Intervention: B-ALL protocol
Number of subjects: 175
Study 17106751 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of ifosfamide 3 g/m2/day for 3 days (9 g/m2/cycle)
Number of subjects: 12
Study 17106751 — intervention group
Group type: COMPARATOR
Intervention: Short (3 h) infusion of ifosfamide 3 g/m2/day for 3 days (9 g/m2/cycle)
Number of subjects: 12
Study 17106751 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of ifosfamide
Number of subjects: 12
Study 17106751 — intervention group
Group type: COMPARATOR
Intervention: Short (3 h) infusion of ifosfamide
Number of subjects: 12
Study 14713402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent human parathyroid hormone (PTH) - teriparatide (recombinant human PTH 1‐34), self-administered daily injections.
Number of subjects: 0
Study 11488370 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term antidepressant treatment
Number of subjects: 7
Study 11488370 — intervention group
Group type: COMPARATOR
Intervention: Mood-stabilizing agents alone
Number of subjects: 7
Study 11488370 — intervention group
Group type: COMPARATOR
Intervention: Mood-stabilizing agents combined with antidepressants
Number of subjects: 7
Study 10511413 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (8.0 g total dose over 1 month)
Number of subjects: 0
Study 10511413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2068440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (5 mg/kg/d)
Number of subjects: 38
Study 2068440 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (2 mg/kg/d)
Number of subjects: 38
Study 6402075 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up measurements (number of visits)
Number of subjects: 110
Study 30898173 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture to Lianquan (CV 23) and Fengfu (GV 16) for 15 min
Number of subjects: 40
Study 30898173 — intervention group
Group type: COMPARATOR
Intervention: Sham electro-acupuncture for 15 min
Number of subjects: 40
Study 29628196 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized knee injection cocktail and oral acetaminophen (standard group)
Number of subjects: 0
Study 29628196 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine periarticular injection and oral acetaminophen (LB group)
Number of subjects: 0
Study 29628196 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized knee injection cocktail and intravenous (IV) acetaminophen (IVA group)
Number of subjects: 0
Study 28273870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber cookie (24 g fiber from distarch phosphate)
Number of subjects: 28
Study 28273870 — intervention group
Group type: COMPARATOR
Intervention: Control cookie (0.5 g fiber)
Number of subjects: 28
Study 23336703 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded activity
Number of subjects: 66
Study 23336703 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise
Number of subjects: 66
Study 21416234 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time withdrawal symptom data collection via palmtop computers for 4 weeks (2 weeks pre-quit and 2 weeks post-quit)
Number of subjects: 1504
Study 21416234 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time reports of craving and negative affect
Number of subjects: 1504
Study 21416234 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression analyses
Number of subjects: 1504
Study 19112278 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion (4 mmol/kg)
Number of subjects: 100
Study 17309328 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study 17309328 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 17309328 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Number of subjects: 0
Study 17309328 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 0
Study 15517671 — intervention group
Group type: EXPERIMENTAL
Intervention: Periurethral injection
Number of subjects: 40
Study 15517671 — intervention group
Group type: COMPARATOR
Intervention: Transurethral injection
Number of subjects: 40
Study 11510636 — intervention group
Group type: EXPERIMENTAL
Intervention: Malek's surgical protocol (modified at HRCA), lip and soft palate repair at 5.5 months, hard palate repair at 20 months
Number of subjects: 75
Study 11510636 — intervention group
Group type: COMPARATOR
Intervention: HRCA surgical protocol, lip repair between 3 and 27 months (mean 9 months), palate repair between 12 and 44 months (mean 19 months)
Number of subjects: 75
Study 10514756 — intervention group
Group type: EXPERIMENTAL
Intervention: Musical therapy
Number of subjects: 30
Study 10514756 — intervention group
Group type: COMPARATOR
Intervention: Control group (no musical therapy)
Number of subjects: 30
Study 8056006 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (100 U.kg‐1 intravenously bolus before thrombolytic treatment and additional intravenous heparin to raise partial thromboplastin time to 2-2.5 times normal)
Number of subjects: 38
Study 8056006 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (Group 1)
Number of subjects: 38
Study 8056006 — intervention group
Group type: COMPARATOR
Intervention: Control (no heparin, Group 2)
Number of subjects: 38
Study 2685187 — intervention group
Group type: COMPARATOR
Intervention: Pefloxacin
Number of subjects: 25
Study 2685187 — intervention group
Group type: COMPARATOR
Intervention: Cefamandole
Number of subjects: 25
Study 970730 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol salbutamol
Number of subjects: 21
Study 970730 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral salbutamol
Number of subjects: 21
Study 29129482 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged uninterrupted sitting
Number of subjects: 0
Study 29129482 — intervention group
Group type: COMPARATOR
Intervention: Regularly interrupted sitting by brief activity-breaks
Number of subjects: 0
Study 28681366 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Jaw Opening Exercise (MJOE): one set of five repetitions at 80% maximum voluntary contraction (MVC) for 6 seconds, performed four sets a day, five times a week, for six weeks
Number of subjects: 16
Study 28681366 — intervention group
Group type: COMPARATOR
Intervention: Isometric jaw closing exercise (Control): one set of five repetitions at 20% MVC for 6 seconds, performed four sets a day, five times a week, for six weeks
Number of subjects: 16
Study 25891021 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA amplitude, 20 min daily for 5 days)
Number of subjects: 32
Study 25891021 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study 25891021 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (active and sham tDCS)
Number of subjects: 32
Study 23624136 — intervention group
Group type: EXPERIMENTAL
Intervention: distracting mini-meal
Number of subjects: 32
Study 23624136 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin
Number of subjects: 32
Study 23624136 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 32
Study 21455728 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 21455728 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 20
Study 17855151 — intervention group
Group type: EXPERIMENTAL
Intervention: High-skill boys
Number of subjects: 0
Study 17855151 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased play area for boys
Number of subjects: 0
Study 17855151 — intervention group
Group type: COMPARATOR
Intervention: Girls
Number of subjects: 0
Study 16507605 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (1,000 IU/day)
Number of subjects: 32
Study 16507605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16507605 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (downhill running for 45 min at 75% maximal oxygen consumption)
Number of subjects: 32
Study 16507605 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced responses
Number of subjects: 32
Study 12601267 — intervention group
Group type: COMPARATOR
Intervention: General exercise training (GET)
Number of subjects: 24
Study 12601267 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise training (GET) and additional eccentric exercise training (EET)
Number of subjects: 24
Study 12601267 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise training (EET)
Number of subjects: 24
Study 11137262 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal group C/CRM (197) conjugate vaccine (3 doses at 2, 3, and 4 months)
Number of subjects: 248
Study 11137262 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (3 doses)
Number of subjects: 248
Study 11137262 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal group C/CRM (197) conjugate vaccine
Number of subjects: 248
Study 9087155 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal antiinflammatory drugs (excluding those reported by the patient as responsible for previous reactions)
Number of subjects: 21
Study 9087155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazole derivatives (most common nonsteroidal antiinflammatory drugs involved)
Number of subjects: 21
Study 9087155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7683800 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 12
Study 7683800 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 12
Study 3300120 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-fosfomycin (M-F)
Number of subjects: 381
Study 3300120 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole-gentamicin (M-G)
Number of subjects: 381
Study 28703951 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (n = 102)
Number of subjects: 353
Study 28703951 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 96)
Number of subjects: 353
Study 26932256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue tolerable plasma (TTP) administered six times each 7 days
Number of subjects: 8
Study 26932256 — intervention group
Group type: COMPARATOR
Intervention: Control (nystatin, chlorhexidine and placebo treatment)
Number of subjects: 8
Study 26573041 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH Agonist Microdose Flareup (MF)
Number of subjects: 123
Study 26573041 — intervention group
Group type: COMPARATOR
Intervention: GnRH Antagonist/Letrozole (AL)
Number of subjects: 123
Study 23840403 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART and TB treatment
Number of subjects: 0
Study 22024700 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral levofloxacin
Number of subjects: 15
Study 22024700 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral ciprofloxacin
Number of subjects: 15
Study 22024700 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg levofloxacin and 250 mg ciprofloxacin co-administered
Number of subjects: 15
Study 18780198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine at 21:00 h
Number of subjects: 90
Study 18780198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine at 17:00 h
Number of subjects: 90
Study 18780198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine at 10:30 h
Number of subjects: 90
Study 16493496 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (4 g daily)
Number of subjects: 300
Study 16493496 — intervention group
Group type: COMPARATOR
Intervention: corn oil (4 g daily)
Number of subjects: 300
Study 12867313 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-l volume air pocket
Number of subjects: 12
Study 12867313 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-l volume air pocket
Number of subjects: 12
Study 12867313 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall tests
Number of subjects: 12
Study 10606835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg daily
Number of subjects: 12
Study 10606835 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 12
Study 9107154 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-chlorophenylpiperazine (m-CPP) infusion (0.08 mg/kg)
Number of subjects: 32
Study 9107154 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 32
Study 9107154 — intervention group
Group type: COMPARATOR
Intervention: Light treatment
Number of subjects: 32
Study 8219179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified worker motivation through special regular sessions and closer supervision
Number of subjects: 1300
Study 8219179 — intervention group
Group type: COMPARATOR
Intervention: Usual procedures
Number of subjects: 1300
Study 3902199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CACP) + 5-fluorouracil (5-FU) infusion (CACP 100 mg/m2 day 1 and 5-FU 1000 mg/m2 24-hour infusion days 1-4)
Number of subjects: 44
Study 3902199 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CACP) + 5-fluorouracil (5-FU) bolus (CACP 100 mg/m2 day 1 and 5-FU 600 mg/m2 day 1 and day 8)
Number of subjects: 44
Study 3902199 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin + 5-FU bolus
Number of subjects: 44
Study 3902199 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + 5-FU infusion
Number of subjects: 44
Study 3902199 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete responders on either arm
Number of subjects: 44
Study 3902199 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial responders on either arm
Number of subjects: 44
Study 30049256 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex bead array (MBA)
Number of subjects: 118
Study 30049256 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-linked immunosorbent assay (ELISA)
Number of subjects: 118
Study 30049256 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral flow assay (LFA)
Number of subjects: 118
Study 30049256 — intervention group
Group type: EXPERIMENTAL
Intervention: All three tests (MBA, ELISA, LFA)
Number of subjects: 118
Study 30049256 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one test (MBA, ELISA, LFA)
Number of subjects: 118
Study 26684046 — intervention group
Group type: EXPERIMENTAL
Intervention: FS-LASIK
Number of subjects: 197
Study 26684046 — intervention group
Group type: COMPARATOR
Intervention: SMILE
Number of subjects: 197
Study 24866923 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship Care Plan (SCP) provided to PCPs
Number of subjects: 266
Study 24866923 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no SCP provided)
Number of subjects: 266
Study 24866923 — intervention group
Group type: EXPERIMENTAL
Intervention: SCP provided to PCPs
Number of subjects: 266
Study 24025632 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 0
Study 24025632 — intervention group
Group type: EXPERIMENTAL
Intervention: α-tocopherol
Number of subjects: 0
Study 24025632 — intervention group
Group type: COMPARATOR
Intervention: Cured meat (nonsupplemented)
Number of subjects: 0
Study 21037028 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment with accelerated functional rehabilitation
Number of subjects: 144
Study 21037028 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment with accelerated functional rehabilitation
Number of subjects: 144
Study 19134433 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil (VCO)
Number of subjects: 26
Study 19134433 — intervention group
Group type: COMPARATOR
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 26
Study 16178832 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-based learning (TBL)
Number of subjects: 83
Study 16178832 — intervention group
Group type: COMPARATOR
Intervention: Case-based group discussion (CBGD)
Number of subjects: 83
Study 12505552 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment for insomnia
Number of subjects: 209
Study 12505552 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychological treatment)
Number of subjects: 209
Study 10211848 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (25 mg)
Number of subjects: 10
Study 10211848 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU)
Number of subjects: 10
Study 10211848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10211848 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (running at 65-70% of VO2max to exhaustion)
Number of subjects: 10